Literature DB >> 35437668

Gallbladder Cancer: A Single-Institution 10-Year Experience-Analysis of Adenocarcinoma Subtypes and Tumors Arising from Intracholecystic Papillary Neoplasms.

Yael Berger1, Brianne J Sullivan2, Natasha L Leigh2, Eliahu Y Bekhor2, Pooja Dhorajiya3, Malary Mani2, Deepa R Magge2, Da Eun Cha2, Umut Sarpel2, Spiros P Hiotis2, Daniel M Labow2, Stephen C Ward3, Benjamin J Golas2, Noah A Cohen2.   

Abstract

BACKGROUND: Gallbladder cancer accounts for 1.2% of global cancer diagnoses. Literature on biliary-type adenocarcinoma (BTA), and specifically carcinoma arising from intracholecystic papillary-tubular neoplasms (ICPNs), is limited. This study describes a retrospective, single-institution experience with gallbladder cancer, focusing on histological subtypes and prognosis.
METHODS: A retrospective review was performed of patients who underwent cholecystectomy for a malignant neoplasm of the gallbladder between 2007 and 2017. Demographic, clinicopathologic, and operative variables, as well as survival outcomes, were analyzed.
RESULTS: From a total of 145 patients, BTAs were most common (93, 64%). Compared with non-BTAs, BTAs were diagnosed at a lower American Joint Committee on Cancer stage (p = 0.045) and demonstrated longer median recurrence-free survival (38 vs. 16 months, p = 0.014; median follow-up 36 months). Tumors arising from ICPNs (18, 12%) were more commonly associated with BTA (14 cases). Compared with BTAs not associated with ICPNs (29 patients), associated cases demonstrated lower pathologic stage (p = 0.006) and lower rates of liver and perineural invasion (0% vs. 49% and 14% vs. 48%, respectively; p < 0.05). Cumulative 5-year survival probability was higher for patients with gallbladder neoplasm of any subtype associated with ICPNs compared with those that were not associated with ICPNs (54% vs. 41%, p = 0.019; median follow-up 23 months). This difference was also significant when comparing BTAs associated with ICPNs and non-associated cases (63% vs. 52%, p = 0.005).
CONCLUSIONS: This study demonstrated unique pathological and prognostic features of BTAs and of carcinomas arising from ICPNs. Histopathological variance may implicate prognosis and may be used to better guide clinical decision making in the treatment of these patients.
© 2022. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2022        PMID: 35437668     DOI: 10.1245/s10434-022-11719-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  27 in total

1.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Authors:  John N Primrose; Richard P Fox; Daniel H Palmer; Hassan Z Malik; Raj Prasad; Darius Mirza; Alan Anthony; Pippa Corrie; Stephen Falk; Meg Finch-Jones; Harpreet Wasan; Paul Ross; Lucy Wall; Jonathan Wadsley; Jeff T R Evans; Deborah Stocken; Raaj Praseedom; Yuk Ting Ma; Brian Davidson; John P Neoptolemos; Tim Iveson; James Raftery; Shihua Zhu; David Cunningham; O James Garden; Clive Stubbs; Juan W Valle; John Bridgewater
Journal:  Lancet Oncol       Date:  2019-03-25       Impact factor: 41.316

2.  Primary Gallbladder Neuroendocrine Tumors: Insights into a Rare Histology Using a Large National Database.

Authors:  Reed I Ayabe; Michael Wach; Samantha Ruff; Sean Martin; Laurence Diggs; Timothy Wiemken; Leslie Hinyard; Jeremy L Davis; Carrie Luu; Jonathan M Hernandez
Journal:  Ann Surg Oncol       Date:  2019-05-17       Impact factor: 5.344

Review 3.  Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

Authors:  Jason K Sicklick; Paul T Fanta; Kelly Shimabukuro; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2016-06       Impact factor: 9.264

4.  The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - A systematic review.

Authors:  Abdul R Hakeem; Michail Papoulas; Krishna V Menon
Journal:  Eur J Surg Oncol       Date:  2018-09-07       Impact factor: 4.424

5.  Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer.

Authors:  Kota Sahara; Diamantis I Tsilimigras; Yutaro Kikuchi; Cecilia G Ethun; Shishir K Maithel; Daniel E Abbott; George A Poultsides; Ioannis Hatzaras; Ryan C Fields; Matthew Weiss; Charles Scoggins; Chelsea A Isom; Kamran Idrees; Perry Shen; Yasuhiro Yabushita; Ryusei Matsuyama; Itaru Endo; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-09-05       Impact factor: 5.344

Review 6.  Gallbladder Cancer in the 21st Century.

Authors:  Rani Kanthan; Jenna-Lynn Senger; Shahid Ahmed; Selliah Chandra Kanthan
Journal:  J Oncol       Date:  2015-09-01       Impact factor: 4.375

Review 7.  Gallbladder cancer: epidemiology and outcome.

Authors:  Rajveer Hundal; Eldon A Shaffer
Journal:  Clin Epidemiol       Date:  2014-03-07       Impact factor: 4.790

Review 8.  Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.

Authors:  Aarti Sharma; Kiran Lata Sharma; Annapurna Gupta; Alka Yadav; Ashok Kumar
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

9.  Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma.

Authors:  Tae Hyun Kim; Sang Myung Woo; Woo Jin Lee; Eun Sang Oh; Sang Hee Youn; Sung Ho Moon; Sang Soo Kim; Sung Sik Han; Sang-Jae Park; Dae Yong Kim
Journal:  Sci Rep       Date:  2019-08-13       Impact factor: 4.379

10.  Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis.

Authors:  Ning Ma; Hui Cheng; Baodong Qin; Renqian Zhong; Bin Wang
Journal:  BMC Cancer       Date:  2015-09-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.